Does LERCANIDIPINE Cause Interstitial lung disease? 86 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 86 reports of Interstitial lung disease have been filed in association with LERCANIDIPINE. This represents 2.3% of all adverse event reports for LERCANIDIPINE.
86
Reports of Interstitial lung disease with LERCANIDIPINE
2.3%
of all LERCANIDIPINE reports
16
Deaths
44
Hospitalizations
How Dangerous Is Interstitial lung disease From LERCANIDIPINE?
Of the 86 reports, 16 (18.6%) resulted in death, 44 (51.2%) required hospitalization, and 14 (16.3%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LERCANIDIPINE. However, 86 reports have been filed with the FAERS database.
What Other Side Effects Does LERCANIDIPINE Cause?
Acute kidney injury (424)
Hypotension (401)
Fall (323)
Hypertension (197)
Hyperkalaemia (176)
Drug ineffective (149)
Diarrhoea (122)
Hyponatraemia (122)
Renal impairment (120)
Oedema peripheral (114)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which LERCANIDIPINE Alternatives Have Lower Interstitial lung disease Risk?
LERCANIDIPINE vs LETAIRIS
LERCANIDIPINE vs LETERMOVIR
LERCANIDIPINE vs LETROZOLE
LERCANIDIPINE vs LETROZOLE\RIBOCICLIB
LERCANIDIPINE vs LEUCOVORIN